<DOC>
	<DOCNO>NCT00041574</DOCNO>
	<brief_summary>The purpose program evaluate logistic issue patient requirement chronic pulse INOmax delivery ambulatory , home-care patient . To understand patient need , patient variety underlying disease include . Safety chronic therapy monitor serial measurement methemoglobin , platelet function assay report adverse event .</brief_summary>
	<brief_title>Hospital-Based Program Treatment Severe Cardiopulmonary Disease With Inhaled Nitric Oxide</brief_title>
	<detailed_description>This study help develop comprehensive home care program use INOmax delivery system . This study enroll limit number patient ( 5-7 ) several disease category order develop experience test acute chronic responsiveness INO therapy . The follow group test : 1 . Primary pulmonary hypertension ( PPH ) 2 . Severe pulmonary hypertension due congenital ( anatomic ) heart disease 3 . Pulmonary hypertension severe impairment gas exchange infant child chronic lung disease 4 . Pulmonary hypertension severe impairment gas exchange due severe chronic lung disease adult 5 . Pulmonary hypertension severe impairment gas exchange hematologic transplant disorder - young child adult sickle cell disease , chronic lung disease bone marrow transplant , cardiac transplant , lung transplant</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Pulmonary Heart Disease</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>Inclusion criterion : Patients pulmonary arterial hypertension ( PAH ) define mean pulmonary artery pressure ( PAP ) 25 mmHg great cardiac catheterization within previous 12 month AND/OR Patients chronic lung disease severe impairment gas exchange unresponsive conventional medical management . If patient receive prostacyclin infusion treatment must start least one month prior start INO therapy . Patients withdraw study start medication treatment pulmonary hypertension . Ability establish clinical investigator drug shipment site local area . The Principal Investigator determine patient and/or caregiver is/are unable manage safe administration home nitric oxide therapy maintain appropriate drug accountability storage . Women pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>